Cargando…

Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a randomized, placebo-controlled study

OBJECTIVE: Canagliflozin, a sodium glucose cotransporter (SGLT) 2 inhibitor, is also a low-potency SGLT1 inhibitor. This study tested the hypothesis that intestinal canagliflozin levels postdose are sufficiently high to transiently inhibit intestinal SGLT1, thereby delaying intestinal glucose absorp...

Descripción completa

Detalles Bibliográficos
Autores principales: Polidori, David, Sha, Sue, Mudaliar, Sunder, Ciaraldi, Theodore P., Ghosh, Atalanta, Vaccaro, Nicole, Farrell, Kristin, Rothenberg, Paul, Henry, Robert R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714520/
https://www.ncbi.nlm.nih.gov/pubmed/23412078
http://dx.doi.org/10.2337/dc12-2391
_version_ 1782277372228141056
author Polidori, David
Sha, Sue
Mudaliar, Sunder
Ciaraldi, Theodore P.
Ghosh, Atalanta
Vaccaro, Nicole
Farrell, Kristin
Rothenberg, Paul
Henry, Robert R.
author_facet Polidori, David
Sha, Sue
Mudaliar, Sunder
Ciaraldi, Theodore P.
Ghosh, Atalanta
Vaccaro, Nicole
Farrell, Kristin
Rothenberg, Paul
Henry, Robert R.
author_sort Polidori, David
collection PubMed
description OBJECTIVE: Canagliflozin, a sodium glucose cotransporter (SGLT) 2 inhibitor, is also a low-potency SGLT1 inhibitor. This study tested the hypothesis that intestinal canagliflozin levels postdose are sufficiently high to transiently inhibit intestinal SGLT1, thereby delaying intestinal glucose absorption. RESEARCH DESIGN AND METHODS: This two-period, crossover study evaluated effects of canagliflozin on intestinal glucose absorption in 20 healthy subjects using a dual-tracer method. Placebo or canagliflozin 300 mg was given 20 min before a 600-kcal mixed-meal tolerance test. Plasma glucose, (3)H-glucose, (14)C-glucose, and insulin were measured frequently for 6 h to calculate rates of appearance of oral glucose (R(a)O) in plasma, endogenous glucose production, and glucose disposal. RESULTS: Compared with placebo, canagliflozin treatment reduced postprandial plasma glucose and insulin excursions (incremental 0- to 2-h area under the curve [AUC(0–2h)] reductions of 35% and 43%, respectively; P < 0.001 for both), increased 0- to 6-h urinary glucose excretion (UGE(0–6h), 18.2 ± 5.6 vs. <0.2 g; P < 0.001), and delayed R(a)O. Canagliflozin reduced AUC R(a)O by 31% over 0 to 1 h (geometric means, 264 vs. 381 mg/kg; P < 0.001) and by 20% over 0 to 2 h (576 vs. 723 mg/kg; P = 0.002). Over 2 to 6 h, canagliflozin increased R(a)O such that total AUC R(a)O over 0 to 6 h was <6% lower versus placebo (960 vs. 1,018 mg/kg; P = 0.003). A modest (∼10%) reduction in acetaminophen absorption was observed over the first 2 h, but this difference was not sufficient to explain the reduction in R(a)O. Total glucose disposal over 0 to 6 h was similar across groups. CONCLUSIONS: Canagliflozin reduces postprandial plasma glucose and insulin by increasing UGE (via renal SGLT2 inhibition) and delaying R(a)O, likely due to intestinal SGLT1 inhibition.
format Online
Article
Text
id pubmed-3714520
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-37145202014-08-01 Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a randomized, placebo-controlled study Polidori, David Sha, Sue Mudaliar, Sunder Ciaraldi, Theodore P. Ghosh, Atalanta Vaccaro, Nicole Farrell, Kristin Rothenberg, Paul Henry, Robert R. Diabetes Care Original Research OBJECTIVE: Canagliflozin, a sodium glucose cotransporter (SGLT) 2 inhibitor, is also a low-potency SGLT1 inhibitor. This study tested the hypothesis that intestinal canagliflozin levels postdose are sufficiently high to transiently inhibit intestinal SGLT1, thereby delaying intestinal glucose absorption. RESEARCH DESIGN AND METHODS: This two-period, crossover study evaluated effects of canagliflozin on intestinal glucose absorption in 20 healthy subjects using a dual-tracer method. Placebo or canagliflozin 300 mg was given 20 min before a 600-kcal mixed-meal tolerance test. Plasma glucose, (3)H-glucose, (14)C-glucose, and insulin were measured frequently for 6 h to calculate rates of appearance of oral glucose (R(a)O) in plasma, endogenous glucose production, and glucose disposal. RESULTS: Compared with placebo, canagliflozin treatment reduced postprandial plasma glucose and insulin excursions (incremental 0- to 2-h area under the curve [AUC(0–2h)] reductions of 35% and 43%, respectively; P < 0.001 for both), increased 0- to 6-h urinary glucose excretion (UGE(0–6h), 18.2 ± 5.6 vs. <0.2 g; P < 0.001), and delayed R(a)O. Canagliflozin reduced AUC R(a)O by 31% over 0 to 1 h (geometric means, 264 vs. 381 mg/kg; P < 0.001) and by 20% over 0 to 2 h (576 vs. 723 mg/kg; P = 0.002). Over 2 to 6 h, canagliflozin increased R(a)O such that total AUC R(a)O over 0 to 6 h was <6% lower versus placebo (960 vs. 1,018 mg/kg; P = 0.003). A modest (∼10%) reduction in acetaminophen absorption was observed over the first 2 h, but this difference was not sufficient to explain the reduction in R(a)O. Total glucose disposal over 0 to 6 h was similar across groups. CONCLUSIONS: Canagliflozin reduces postprandial plasma glucose and insulin by increasing UGE (via renal SGLT2 inhibition) and delaying R(a)O, likely due to intestinal SGLT1 inhibition. American Diabetes Association 2013-08 2013-07-11 /pmc/articles/PMC3714520/ /pubmed/23412078 http://dx.doi.org/10.2337/dc12-2391 Text en © 2013 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
spellingShingle Original Research
Polidori, David
Sha, Sue
Mudaliar, Sunder
Ciaraldi, Theodore P.
Ghosh, Atalanta
Vaccaro, Nicole
Farrell, Kristin
Rothenberg, Paul
Henry, Robert R.
Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a randomized, placebo-controlled study
title Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a randomized, placebo-controlled study
title_full Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a randomized, placebo-controlled study
title_fullStr Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a randomized, placebo-controlled study
title_full_unstemmed Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a randomized, placebo-controlled study
title_short Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a randomized, placebo-controlled study
title_sort canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714520/
https://www.ncbi.nlm.nih.gov/pubmed/23412078
http://dx.doi.org/10.2337/dc12-2391
work_keys_str_mv AT polidoridavid canagliflozinlowerspostprandialglucoseandinsulinbydelayingintestinalglucoseabsorptioninadditiontoincreasingurinaryglucoseexcretionresultsofarandomizedplacebocontrolledstudy
AT shasue canagliflozinlowerspostprandialglucoseandinsulinbydelayingintestinalglucoseabsorptioninadditiontoincreasingurinaryglucoseexcretionresultsofarandomizedplacebocontrolledstudy
AT mudaliarsunder canagliflozinlowerspostprandialglucoseandinsulinbydelayingintestinalglucoseabsorptioninadditiontoincreasingurinaryglucoseexcretionresultsofarandomizedplacebocontrolledstudy
AT ciaralditheodorep canagliflozinlowerspostprandialglucoseandinsulinbydelayingintestinalglucoseabsorptioninadditiontoincreasingurinaryglucoseexcretionresultsofarandomizedplacebocontrolledstudy
AT ghoshatalanta canagliflozinlowerspostprandialglucoseandinsulinbydelayingintestinalglucoseabsorptioninadditiontoincreasingurinaryglucoseexcretionresultsofarandomizedplacebocontrolledstudy
AT vaccaronicole canagliflozinlowerspostprandialglucoseandinsulinbydelayingintestinalglucoseabsorptioninadditiontoincreasingurinaryglucoseexcretionresultsofarandomizedplacebocontrolledstudy
AT farrellkristin canagliflozinlowerspostprandialglucoseandinsulinbydelayingintestinalglucoseabsorptioninadditiontoincreasingurinaryglucoseexcretionresultsofarandomizedplacebocontrolledstudy
AT rothenbergpaul canagliflozinlowerspostprandialglucoseandinsulinbydelayingintestinalglucoseabsorptioninadditiontoincreasingurinaryglucoseexcretionresultsofarandomizedplacebocontrolledstudy
AT henryrobertr canagliflozinlowerspostprandialglucoseandinsulinbydelayingintestinalglucoseabsorptioninadditiontoincreasingurinaryglucoseexcretionresultsofarandomizedplacebocontrolledstudy